Seikagaku reported FY 2Q21 orthopedic sales of $42.3 million (¥4,402), +35.9% vs. FY 2Q20. Compared to the same period in 2019, the company grew +2.5%. For the full fiscal year ending March 31, 2022, Seikagaku expects growth of +16% vs. 2020.
The company is rounding the corner on offsetting drug price reductions in Japan via market share gains and an overall market rebound from the pandemic low point. Leadership also called out a substantial increase in royalty revenue as a growth driver in the quarter. Seikagaku’s single-injection and five-injection treatments both performed well in the U.S.and benefitted from order timing as distributors look to avoid supply shortages.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
2Q21
2Q20
$ Chg
% Chg
Orthobiologics
$42.3
$31.1
$11.2
35.9%
1H21
1H20
$ Chg
% Chg
Orthobiologics
$75.5
$60.2
$15.3
25.5%
Orthopedic Sales by Geography
2Q21
2Q20
$ Chg
% Chg
Domestic (Japan)
$13.6
$11.9
$1.7
14.5%
International
$28.6
$19.2
$9.4
49.2%
Total
$42.3
$31.1
$11.2
35.9%
1H21
1H20
$ Chg
% Chg
Domestic (Japan)
$30.2
$28.9
$1.3
4.6%
International
$45.3
$31.2
$14.0
44.9%
Total
$75.5
$60.2
$15.3
25.5%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY 2Q21 orthopedic sales of $42.3 million (¥4,402), +35.9% vs. FY 2Q20. Compared to the same period in 2019, the company grew +2.5%. For the full fiscal year ending March 31, 2022, Seikagaku expects growth of +16% vs. 2020.
The company is rounding the corner on offsetting drug price reductions in Japan via market share...
Seikagaku reported FY 2Q21 orthopedic sales of $42.3 million (¥4,402), +35.9% vs. FY 2Q20. Compared to the same period in 2019, the company grew +2.5%. For the full fiscal year ending March 31, 2022, Seikagaku expects growth of +16% vs. 2020.
The company is rounding the corner on offsetting drug price reductions in Japan via market share gains and an overall market rebound from the pandemic low point. Leadership also called out a substantial increase in royalty revenue as a growth driver in the quarter. Seikagaku’s single-injection and five-injection treatments both performed well in the U.S.and benefitted from order timing as distributors look to avoid supply shortages.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
2Q21
2Q20
$ Chg
% Chg
Orthobiologics
$42.3
$31.1
$11.2
35.9%
1H21
1H20
$ Chg
% Chg
Orthobiologics
$75.5
$60.2
$15.3
25.5%
Orthopedic Sales by Geography
2Q21
2Q20
$ Chg
% Chg
Domestic (Japan)
$13.6
$11.9
$1.7
14.5%
International
$28.6
$19.2
$9.4
49.2%
Total
$42.3
$31.1
$11.2
35.9%
1H21
1H20
$ Chg
% Chg
Domestic (Japan)
$30.2
$28.9
$1.3
4.6%
International
$45.3
$31.2
$14.0
44.9%
Total
$75.5
$60.2
$15.3
25.5%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
